Literature DB >> 2200125

Specific tropism of HIV-1 for microglial cells in primary human brain cultures.

B A Watkins1, H H Dorn, W B Kelly, R C Armstrong, B J Potts, F Michaels, C V Kufta, M Dubois-Dalcq.   

Abstract

Human immunodeficiency virus (HIV) frequently causes neurological dysfunction and is abundantly expressed in the central nervous system (CNS) of acquired immunodeficiency syndrome (AIDS) patients with HIV encephalitis or myelopathy. The virus is found mostly in cells of the monocyte-macrophage lineage within the CNS, but the possibility of infection of other glial cells has been raised. Therefore, the effects of different HIV-1 and HIV-2 strains were studied in primary cultures of adult human brain containing microglial cells, the resident CNS macrophages, and astrocytes. These cultures could be productively infected with macrophage-adapted HIV-1 isolates but not with T lymphocyte-adapted HIV-1 isolates or two HIV-2 isolates. As determined with a triple-label procedure, primary astrocytes did not express HIV gag antigens and remained normal throughout the 3-week course of infection. In contrast, virus replicated in neighboring microglial cells, often leading to their cell fusion and death. The death of microglial cells, which normally serve immune functions in the CNS, may be a key factor in the pathogenesis of AIDS encephalitis or myelopathy.

Entities:  

Mesh:

Year:  1990        PMID: 2200125     DOI: 10.1126/science.2200125

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  107 in total

1.  CD4/CXCR4-independent infection of human astrocytes by a T-tropic strain of HIV-1.

Authors:  B Schweighardt; J T Shieh; W J Atwood
Journal:  J Neurovirol       Date:  2001-04       Impact factor: 2.643

Review 2.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

3.  CXCR4 is the primary receptor for feline immunodeficiency virus in astrocytes.

Authors:  K Nakagaki; K Nakagaki; K Takahashi; D Schols; E De Clercq; T Tabira
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643

Review 4.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo.

Authors:  J A Mikovits; N C Lohrey; R Schulof; J Courtless; F W Ruscetti
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 6.  Neurotoxicity of macrophages infected by HIV1.

Authors:  M Tardieu; C Hery; S Peudenier
Journal:  Cell Biol Toxicol       Date:  1992 Jul-Sep       Impact factor: 6.691

7.  Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: implications for AIDS dementia complex.

Authors:  D J Benos; B H Hahn; J K Bubien; S K Ghosh; N A Mashburn; M A Chaikin; G M Shaw; E N Benveniste
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

9.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.

Authors:  C A Spina; J C Guatelli; D D Richman
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.